These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 33199274)

  • 1. Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.
    Dakin P; Kivitz AJ; Gimbel JS; Skrepnik N; DiMartino SJ; Emeremni CA; Gao H; Stahl N; Weinreich DM; Yancopoulos GD; Geba GP
    Ann Rheum Dis; 2021 Apr; 80(4):509-517. PubMed ID: 33199274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Dakin P; DiMartino SJ; Gao H; Maloney J; Kivitz AJ; Schnitzer TJ; Stahl N; Yancopoulos GD; Geba GP
    Arthritis Rheumatol; 2019 Nov; 71(11):1824-1834. PubMed ID: 31207169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain.
    Kivitz AJ; Gimbel JS; Bramson C; Nemeth MA; Keller DS; Brown MT; West CR; Verburg KM
    Pain; 2013 Jul; 154(7):1009-21. PubMed ID: 23628600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee.
    Tiseo PJ; Kivitz AJ; Ervin JE; Ren H; Mellis SJ
    Pain; 2014 Jul; 155(7):1245-1252. PubMed ID: 24686255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study.
    Sanga P; Polverejan E; Wang S; Kelly KM; Thipphawong J
    Clin Ther; 2016 Jun; 38(6):1435-1450. PubMed ID: 27101815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.
    Markman JD; Bolash RB; McAlindon TE; Kivitz AJ; Pombo-Suarez M; Ohtori S; Roemer FW; Li DJ; Viktrup L; Bramson C; West CR; Verburg KM
    Pain; 2020 Sep; 161(9):2068-2078. PubMed ID: 32453139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
    Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
    JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of duloxetine in patients with chronic low back pain.
    Skljarevski V; Desaiah D; Liu-Seifert H; Zhang Q; Chappell AS; Detke MJ; Iyengar S; Atkinson JH; Backonja M
    Spine (Phila Pa 1976); 2010 Jun; 35(13):E578-85. PubMed ID: 20461028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial.
    Coats TL; Borenstein DG; Nangia NK; Brown MT
    Clin Ther; 2004 Aug; 26(8):1249-60. PubMed ID: 15476906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials.
    Williamson OD; Schroer M; Ruff DD; Ahl J; Margherita A; Sagman D; Wohlreich MM
    Clin Ther; 2014 Apr; 36(4):544-51. PubMed ID: 24650448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixed-dose combination tablet for the treatment of chronic low back pain.
    Lee JH; Lee CS;
    Clin Ther; 2013 Nov; 35(11):1830-40. PubMed ID: 24183364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
    Kivitz A; Ma C; Ahdieh H; Galer BS
    Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tanezumab in the treatment of chronic low back pain.
    Katz N; Borenstein DG; Birbara C; Bramson C; Nemeth MA; Smith MD; Brown MT
    Pain; 2011 Oct; 152(10):2248-2258. PubMed ID: 21696889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study.
    Zerbini C; Ozturk ZE; Grifka J; Maini M; Nilganuwong S; Morales R; Hupli M; Shivaprakash M; Giezek H;
    Curr Med Res Opin; 2005 Dec; 21(12):2037-49. PubMed ID: 16368055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study.
    Tiseo PJ; Ren H; Mellis S
    J Pain Res; 2014; 7():523-30. PubMed ID: 25210473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-nerve growth factor antibodies for the treatment of low back pain.
    Patel F; Hess DK; Maher DP
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):631-639. PubMed ID: 32436473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.